List of therapeutic monoclonal antibodies
This is a list of therapeutic, diagnostic and preventive monoclonal antibodies, antibodies that are clones of a single parent cell. When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies.

Types of monoclonal antibodies with other structures than naturally occurring antibodies.
The abbreviations in the column Type are as follows:
- mab: whole monoclonal antibody
- Fab: fragment, antigen-binding (one arm)
- F(ab')2: fragment, antigen-binding, including hinge region (both arms)
- Fab': fragment, antigen-binding, including hinge region (one arm)
- Variable fragments:
- scFv: single-chain variable fragment
- di-scFv: dimeric single-chain variable fragment
- sdAb: single-domain antibody
- Bispecific monoclonal antibodies:
- 3funct: trifunctional antibody
- BiTE: bi-specific T-cell engager
This list includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage.
Name | Trade name | Type | Source | Target | Use |
---|---|---|---|---|---|
3F8 | mab | mouse | GD2 ganglioside | neuroblastoma | |
8H9[1] | mab | mouse | B7-H3 | neuroblastoma, sarcoma, metastatic brain cancers | |
Abagovomab[2] | mab | mouse | CA-125 (imitation) | ovarian cancer | |
Abciximab | ReoPro | Fab | chimeric | CD41 (integrin alpha-IIb) | platelet aggregation inhibitor |
Abituzumab[3] | mab | humanized | CD51 | cancer | |
Abrilumab[4] | mab | human | integrin α4β7 | inflammatory bowel disease, ulcerative colitis, Crohn's disease | |
Actoxumab[5] | mab | human | Clostridium difficile | Clostridium difficile colitis | |
Adalimumab | Humira | mab | human | TNF-α | Rheumatoid arthritis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hemolytic disease of the newborn |
Adecatumumab[6] | mab | human | EpCAM | prostate and breast cancer | |
Aducanumab[7] | mab | human | beta-amyloid | Alzheimer's disease | |
Afasevikumab[8] | mab | human | IL17A and IL17F | ? | |
Afelimomab | F(ab')2 | mouse | TNF-α | sepsis | |
Afutuzumab[9] | mab | humanized | CD20 | lymphoma | |
Alacizumab pegol[10] | F(ab')2 | humanized | VEGFR2 | cancer | |
ALD518[11] | ? | humanized | IL-6 | rheumatoid arthritis | |
Alemtuzumab[12] | Lemtrada, Campath | mab | humanized | CD52 | Multiple sclerosis |
Alirocumab[13] | mab | human | PCSK9 | hypercholesterolemia | |
Altumomab pentetate | Hybri-ceaker | mab | mouse | CEA | colorectal cancer (diagnosis) |
Amatuximab[14] | mab | chimeric | mesothelin | cancer | |
Anatumomab mafenatox | Fab | mouse | TAG-72 | non-small cell lung carcinoma | |
Anetumab ravtansine[3] | mab | human | MSLN | cancer | |
Anifrolumab[15] | mab | human | interferon α/β receptor | systemic lupus erythematosus | |
Anrukinzumab[10] (= IMA-638)[16] | mab | humanized | IL-13 | asthma | |
Apolizumab[17] | mab | humanized | HLA-DR ? | hematological cancers | |
Arcitumomab | CEA-Scan | Fab' | mouse | CEA | gastrointestinal cancers (diagnosis) |
Ascrinvacumab[18] | mab | human | activin receptor-like kinase 1 | cancer | |
Aselizumab[19] | mab | humanized | L-selectin (CD62L) | severely injured patients | |
Atezolizumab[20] | mab | humanized | CD274 | cancer | |
Atinumab[21] | mab | human | RTN4 | ? | |
Atlizumab (= tocilizumab) | Actemra, RoActemra | mab | humanized | IL-6 receptor | rheumatoid arthritis |
Atorolimumab | mab | human | Rhesus factor | hemolytic disease of the newborn | |
Avelumab[8] | mab | human | CD274 | ? | |
Bapineuzumab[22] | mab | humanized | beta amyloid | Alzheimer's disease | |
Basiliximab | Simulect | mab | chimeric | CD25 (α chain of IL-2 receptor) | prevention of organ transplant rejections |
Bavituximab[2] | mab | chimeric | phosphatidylserine | cancer, viral infections | |
Bectumomab | LymphoScan | Fab' | mouse | CD22 | non-Hodgkin's lymphoma (detection) |
Begelomab[23] | mab | mouse | DPP4 | ? | |
Belimumab | Benlysta, LymphoStat-B | mab | human | BAFF | non-Hodgkin lymphoma etc. |
Benralizumab | mab | humanized | CD125 | asthma | |
Bertilimumab[19] | mab | human | CCL11 (eotaxin-1) | severe allergic disorders | |
Besilesomab[24] | Scintimun | mab | mouse | CEA-related antigen | inflammatory lesions and metastases (detection) |
Bevacizumab[12] | Avastin | mab | humanized | VEGF-A | metastatic cancer, retinopathy of prematurity |
Bezlotoxumab[25] | mab | human | Clostridium difficile | Clostridium difficile colitis | |
Biciromab | FibriScint | Fab' | mouse | fibrin II, beta chain | thromboembolism (diagnosis) |
Bimagrumab[26][27] | mab | human | ACVR2B | myostatin inhibitor | |
Bimekizumab[28] | mab | humanized | IL 17A and IL 17F | ? | |
Bivatuzumab mertansine | mab | humanized | CD44 v6 | squamous cell carcinoma | |
Bleselumab[8] | mab | human | CD40 | ? | |
Blinatumomab | BiTE | mouse | CD19 | pre-B ALL (CD19+) | |
Blontuvetmab[29] | Blontress | mab | veterinary | CD20 | ? |
Blosozumab[30] | mab | humanized | SOST | osteoporosis | |
Bococizumab[31] | mab | humanized | neural apoptosis-regulated proteinase 1 | dyslipidemia | |
Brazikumab[32] | mab | human | IL23 | Crohn's disease | |
Brentuximab vedotin[33] | mab | chimeric | CD30 (TNFRSF8) | hematologic cancers | |
Briakinumab[34] | mab | human | IL-12, IL-23 | psoriasis, rheumatoid arthritis, inflammatory bowel diseases, multiple sclerosis | |
Brodalumab[35] | mab | human | IL-17 | inflammatory diseases | |
Brolucizumab[20] | mab | humanized | VEGFA | wet age-related macular degeneration | |
Brontictuzumab[23] | mab | humanized | Notch 1 | cancer | |
Burosumab[32] | mab | human | FGF 23 | X-linked hypophosphatemia | |
Cabiralizumab[29] | mab | humanized | CSF1R | ? | |
Canakinumab[36] | Ilaris | mab | human | IL-1? | rheumatoid arthritis |
Cantuzumab mertansine | mab | humanized | mucin CanAg | colorectal cancer etc. | |
Cantuzumab ravtansine[30] | mab | humanized | MUC1 | cancers | |
Caplacizumab[37] | mab | humanized | VWF | thrombotic thrombocytopenic purpura, thrombosis | |
Capromab pendetide | Prostascint | mab | mouse | prostatic carcinoma cells | prostate cancer (detection) |
Carlumab[38] | mab | human | MCP-1 | oncology/immune indications | |
Carotuximab[29] | mab | chimeric | endoglin | ? | |
Catumaxomab[22] | Removab | 3funct | rat/mouse hybrid | EpCAM, CD3 | ovarian cancer, malignant ascites, gastric cancer |
cBR96-doxorubicin immunoconjugate | mab | humanized | Lewis-Y antigen | cancer | |
Cedelizumab | mab | humanized | CD4 | prevention of organ transplant rejections, treatment of autoimmune diseases | |
Cergutuzumab amunaleukin[8] | mab | humanized | IL2 | ? | |
Certolizumab pegol[6] | Cimzia | Fab' | humanized | TNF-α | Crohn's disease Rheumatoid arthritis axial spondyloarthritis psoriasis arthritis |
Cetuximab | Erbitux | mab | chimeric | EGFR | metastatic colorectal cancer and head and neck cancer |
Ch.14.18 [1] | mab | chimeric | GD2 ganglioside | neuroblastoma | |
Citatuzumab bogatox[9] | Fab | humanized | EpCAM | ovarian cancer and other solid tumors | |
Cixutumumab | mab | human | IGF-1 receptor (CD221) | solid tumors | |
Clazakizumab[39] | mab | humanized | Oryctolagus cuniculus | rheumatoid arthritis | |
Clenoliximab | mab | chimeric | CD4 | rheumatoid arthritis | |
Clivatuzumab tetraxetan[40] | hPAM4-Cide | mab | humanized | MUC1 | pancreatic cancer |
Codrituzumab[3] | mab | humanized | glypican 3 | cancer | |
Coltuximab ravtansine[3] | mab | chimeric | CD19 | cancer | |
Conatumumab[9] | mab | human | TRAIL-R2 | cancer | |
Concizumab[26] | mab | humanized | TFPI | bleeding | |
Crenezumab[41] | mab | humanized | 1-40-β-amyloid | Alzheimer's disease | |
Crotedumab[29] | mab | human | GCGR | diabetes | |
CR6261 | mab | human | Influenza A hemagglutinin | infectious disease/influenza A | |
Dacetuzumab[10] | mab | humanized | CD40 | hematologic cancers | |
Daclizumab | Zenapax | mab | humanized | CD25 (α chain of IL-2 receptor) | prevention of organ transplant rejections |
Dalotuzumab[42] | mab | humanized | IGF-1 receptor (CD221) | cancer etc. | |
Dapirolizumab pegol[28] | mab | humanized | CD154 (CD40L) | ? | |
Daratumumab[43] | mab | human | CD38 (cyclic ADP ribose hydrolase) | cancer | |
Dectrekumab[20] | mab | human | IL-13 | ? | |
Demcizumab[44] | mab | humanized | DLL4 | cancer | |
Denintuzumab mafodotin[23] | mab | humanized | CD19 | cancer | |
Denosumab[45] | Prolia | mab | human | RANKL | osteoporosis, bone metastases etc. |
Depatuxizumab mafodotin[32] | mab | chimeric/humanized | EGFR | cancer | |
Derlotuximab biotin[46] | mab | chimeric | histone complex | recurrent glioblastoma multiforme | |
Detumomab | mab | mouse | B-lymphoma cell | lymphoma | |
Dinutuximab[47] | mab | chimeric | GD2 ganglioside | neuroblastoma | |
Diridavumab[48] | mab | human | hemagglutinin | influenza A | |
Domagrozumab[29] | mab | humanized | GDF-8 | Duchenne muscular dystrophy | |
Dorlimomab aritox[49] | F(ab')2 | mouse | ? | ? | |
Drozitumab[50] | mab | human | DR5 | cancer etc. | |
Duligotumab[51] | mab | human | ERBB3 (HER3) | ? | |
Dupilumab[52] | mab | human | IL4 | atopic diseases | |
Durvalumab[53] | mab | human | CD274 | cancer | |
Dusigitumab[54] | mab | human | ILGF2 | cancer | |
Ecromeximab[17] | mab | chimeric | GD3 ganglioside | malignant melanoma | |
Eculizumab[17] | Soliris | mab | humanized | C5 | paroxysmal nocturnal hemoglobinuria, atypical HUS |
Edobacomab | mab | mouse | endotoxin | sepsis caused by Gram-negative bacteria | |
Edrecolomab | Panorex | mab | mouse | EpCAM | colorectal carcinoma |
Efalizumab[55] | Raptiva | mab | humanized | LFA-1 (CD11a) | psoriasis (blocks T-cell migration) |
Efungumab[2] | Mycograb | scFv | human | Hsp90 | invasive Candida infection |
Eldelumab[56] | mab | human | interferon gamma-induced protein | Crohn's disease, ulcerative colitis | |
Elgemtumab[20] | mab | human | ERBB3 (HER3) | cancer | |
Elotuzumab | mab | humanized | SLAMF7 | multiple myeloma | |
Elsilimomab | mab | mouse | IL-6 | ? | |
Emactuzumab[23] | mab | humanized | CSF1R | cancer | |
Emibetuzumab[57] | mab | humanized | HHGFR | cancer | |
Emicizumab[8] | mab | humanized | activated F9, F10 | haemophilia A | |
Enavatuzumab[58] | mab | humanized | TWEAK receptor | cancer etc. | |
Enfortumab vedotin[59] | mab | human | AGS-22M6 | cancer expressing Nectin-4 | |
Enlimomab pegol[60] | mab | mouse | ICAM-1 (CD54) | ? | |
Enoblituzumab[61] | mab | humanized | CD276 | cancer | |
Enokizumab[62] | mab | humanized | IL9 | asthma | |
Enoticumab[51] | mab | human | DLL4 | ? | |
Ensituximab[63] | mab | chimeric | 5AC | cancer | |
Epitumomab cituxetan[64] | mab | mouse | episialin | ? | |
Epratuzumab | mab | humanized | CD22 | cancer, SLE | |
Erenumab[32] | mab | human | CGRP | migraine | |
Erlizumab[65] | F(ab')2 | humanized | ITGB2 (CD18) | heart attack, stroke, traumatic shock | |
Ertumaxomab[22] | Rexomun | 3funct | rat/mouse hybrid | HER2/neu, CD3 | breast cancer etc. |
Etaracizumab | Abegrin | mab | humanized | integrin αvβ3 | melanoma, prostate cancer, ovarian cancer etc. |
Etrolizumab[66] | mab | humanized | integrin α7 β7 | inflammatory bowel disease | |
Evinacumab[67] | mab | human | angiopoietin 3 | dyslipidemia | |
Evolocumab[26] | mab | human | PCSK9 | hypercholesterolemia | |
Exbivirumab[68] | mab | human | hepatitis B surface antigen | hepatitis B | |
Fanolesomab[69] | NeutroSpec | mab | mouse | CD15 | appendicitis (diagnosis) |
Faralimomab | mab | mouse | interferon receptor | ? | |
Farletuzumab | mab | humanized | folate receptor 1 | ovarian cancer | |
Fasinumab[70] | mab | human | HNGF | acute sciatic pain | |
FBTA05[71][72] | Lymphomun | 3funct | rat/mouse hybrid | CD20 | chronic lymphocytic leukaemia |
Felvizumab | mab | humanized | respiratory syncytial virus | respiratory syncytial virus infection | |
Fezakinumab[73][74][75] | mab | human | IL-22 | rheumatoid arthritis, psoriasis | |
Fibatuzumab[8] | mab | humanized | ephrin receptor A3 | ? | |
Ficlatuzumab[76] | mab | humanized | HGF | cancer etc. | |
Figitumumab | mab | human | IGF-1 receptor (CD221) | adrenocortical carcinoma, non-small cell lung carcinoma etc. | |
Firivumab[23] | mab | human | influenza A virus hemagglutinin | ? | |
Flanvotumab[77] | mab | human | TYRP1(glycoprotein 75) | melanoma | |
Fletikumab[78] | mab | human | IL 20 | rheumatoid arthritis | |
Fontolizumab[17] | HuZAF | mab | humanized | IFN-γ | Crohn's disease etc. |
Foralumab[79] | mab | human | CD3 epsilon | ? | |
Foravirumab[9] | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | |
Fresolimumab[80] | mab | human | TGF-β | idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, cancer | |
Fulranumab[81] | mab | human | NGF | pain | |
Futuximab[51] | mab | chimeric | EGFR | cancer | |
Galcanezumab[29] | mab | humanized | calcitonin | migraine | |
Galiximab | mab | chimeric | CD80 | B-cell lymphoma | |
Ganitumab[82] | mab | human | IGF-1 receptor (CD221) | cancer | |
Gantenerumab[36] | mab | human | beta amyloid | Alzheimer's disease | |
Gavilimomab[65] | mab | mouse | CD147 (basigin) | graft versus host disease | |
Gemtuzumab ozogamicin | Mylotarg | mab | humanized | CD33 | acute myelogenous leukemia |
Gevokizumab[83] | mab | humanized | IL-1β | diabetes etc. | |
Girentuximab[43] | Rencarex | mab | chimeric | carbonic anhydrase 9 (CA-IX) | clear cell renal cell carcinoma[84] |
Glembatumumab vedotin[85][86] | mab | human | GPNMB | melanoma, breast cancer | |
Golimumab[68] | Simponi | mab | human | TNF-α | rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis |
Gomiliximab | mab | chimeric | CD23 (IgE receptor) | allergic asthma | |
Guselkumab[87] | mab | human | IL23 | psoriasis | |
Ibalizumab[36] | mab | humanized | CD4 | HIV infection | |
Ibritumomab tiuxetan | Zevalin | mab | mouse | CD20 | non-Hodgkin's lymphoma |
Icrucumab[88] | mab | human | VEGFR-1 | cancer etc. | |
Idarucizumab[3] | mab | humanized | dabigatran | reversal of anticoagulant effects of dabigatran | |
Igovomab | Indimacis-125 | F(ab')2 | mouse | CA-125 | ovarian cancer (diagnosis) |
IMAB362 | mab | human | CLDN18.2 | gastrointestinal adenocarcinomas and pancreatic tumor | |
Imalumab[23] | mab | human | MIF | cancer | |
Imciromab | Myoscint | mab | mouse | cardiac myosin | cardiac imaging |
Imgatuzumab[51] | mab | humanized | EGFR | cancer | |
Inclacumab[37] | mab | human | selectin P | cardiovascular disease | |
Indatuximab ravtansine[30] | mab | chimeric | SDC1 | cancer | |
Indusatumab vedotin[20] | mab | human | GUCY2C | cancer | |
Inebilizumab[8] | mab | humanized | CD19 | cancer, systemic sclerosis, multiple sclerosis | |
Infliximab | Remicade | mab | chimeric | TNF-α | rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis |
Intetumumab[89][90][91] | mab | human | CD51 | solid tumors (prostate cancer, melanoma) | |
Inolimomab | mab | mouse | CD25 (α chain of IL-2 receptor) | graft versus host disease | |
Inotuzumab ozogamicin[24] | mab | humanized | CD22 | ALL | |
Ipilimumab[45] | Yervoy | mab | human | CD152 | melanoma |
Iratumumab[45] | mab | human | CD30 (TNFRSF8) | Hodgkin's lymphoma | |
Isatuximab[92] | mab | chimeric | CD38 | cancer | |
Itolizumab[79] | mab | humanized | CD6 | ? | |
Ixekizumab[93] | mab | humanized | IL 17A | autoimmune diseases | |
Keliximab | mab | chimeric | CD4 | chronic asthma | |
Labetuzumab[55] | CEA-Cide | mab | humanized | CEA | colorectal cancer |
Lambrolizumab[94] | mab | humanized | PDCD1 | antineoplastic agent | |
Lampalizumab[51] | mab | humanized | CFD | geographic atrophy secondary to age-related macular degeneration | |
Lanadelumab[29] | mab | human | kallikrein | angioedema | |
Landogrozumab[8] | mab | humanized | GDF-8 | muscle wasting disorders | |
Laprituximab emtansine[29] | mab | chimeric | EGFR | ? | |
Lebrikizumab[95] | mab | humanized | IL-13 | asthma | |
Lemalesomab[65] | mab | mouse | NCA-90 (granulocyte antigen) | diagnostic agent | |
Lendalizumab[29] | mab | humanized | C5 | ? | |
Lenzilumab[23] | mab | human | CSF2 | ? | |
Lerdelimumab[12] | mab | human | TGF beta 2 | reduction of scarring after glaucoma surgery | |
Lexatumumab[2] | mab | human | TRAIL-R2 | cancer | |
Libivirumab[68] | mab | human | hepatitis B surface antigen | hepatitis B | |
Lifastuzumab vedotin[96] | mab | humanized | phosphate-sodium co-transporter | cancer | |
Ligelizumab[51][97] | mab | humanized | IGHE | severe asthma and chronic spontaneous urticaria | |
Lilotomab satetraxetan[20] | mab | mouse | CD37 | cancer | |
Lintuzumab | mab | humanized | CD33 | cancer | |
Lirilumab[51] | mab | human | KIR2D | solid and hematological cancers | |
Lodelcizumab[26] | mab | humanized | PCSK9 | hypercholesterolemia | |
Lokivetmab[20] | mab | veterinary | Canis lupus familiaris IL31 | ? | |
Lorvotuzumab mertansine | mab | humanized | CD56 | cancer | |
Lucatumumab[10] | mab | human | CD40 | multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma | |
Lulizumab pegol[98] | mab | humanized | CD28 | autoimmune diseases | |
Lumiliximab[6] | mab | chimeric | CD23 (IgE receptor) | chronic lymphocytic leukemia | |
Lumretuzumab[23] | mab | humanized | ERBB3 (HER3) | cancer | |
Mapatumumab[22] | mab | human | TRAIL-R1 | cancer | |
Margetuximab[99] | mab | humanized | ch4D5 | cancer | |
Maslimomab | ? | mouse | T-cell receptor | ? | |
Mavrilimumab[100] | mab | human | GMCSF receptor α-chain | rheumatoid arthritis | |
Matuzumab[19] | mab | humanized | EGFR | colorectal, lung and stomach cancer | |
Mepolizumab | Bosatria | mab | humanized | IL-5 | asthma and white blood cell diseases |
Metelimumab[69] | mab | human | TGF beta 1 | systemic scleroderma | |
Milatuzumab[10] | mab | humanized | CD74 | multiple myeloma and other hematological malignancies | |
Minretumomab | mab | mouse | TAG-72 | tumor detection (and therapy?) | |
Mirvetuximab soravtansine[101] | mab | chimeric | folate receptor alpha | cancer | |
Mitumomab | mab | mouse | GD3 ganglioside | small cell lung carcinoma | |
Mogamulizumab[102] | mab | humanized | CCR4 | cancer | |
Monalizumab[8] | mab | humanized | KLRC1 | ? | |
Morolimumab | mab | human | Rhesus factor | ? | |
Motavizumab[2] | Numax | mab | humanized | respiratory syncytial virus | respiratory syncytial virus (prevention) |
Moxetumomab pasudotox[103] | mab | mouse | CD22 | cancer | |
Muromonab-CD3 | Orthoclone OKT3 | mab | mouse | CD3 | prevention of organ transplant rejections |
Nacolomab tafenatox | Fab | mouse | C242 antigen | colorectal cancer | |
Namilumab[21] | mab | human | CSF2 | ? | |
Naptumomab estafenatox[104] | Fab | mouse | 5T4 | non-small cell lung carcinoma, renal cell carcinoma | |
Naratuximab emtansine[29] | mab | chimeric | CD37 | ? | |
Narnatumab[105] | mab | human | RON | cancer | |
Natalizumab | Tysabri | mab | humanized | integrin α4 | multiple sclerosis, Crohn's disease |
Navicixizumab[29] | mab | chimeric/humanized | DLL4 | ? | |
Navivumab[8] | mab | human | influenza A virus hemagglutinin HA | ? | |
Nebacumab | mab | human | endotoxin | sepsis | |
Necitumumab[106] | mab | human | EGFR | non-small cell lung carcinoma | |
Nemolizumab[20] | mab | humanized | IL31RA | ? | |
Nerelimomab | mab | mouse | TNF-α | ? | |
Nesvacumab[107] | mab | human | angiopoietin 2 | cancer | |
Nimotuzumab[45][108] | Theracim, Theraloc | mab | humanized | EGFR | squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, glioma |
Nivolumab[109] | Opdivo | mab | human | PD-1 | cancer |
Nofetumomab merpentan | Verluma | Fab | mouse | ? | cancer (diagnosis) |
Obiltoxaximab[110] | mab | chimeric | Bacillus anthracis anthrax | Bacillus anthracis spores | |
Obinutuzumab | Gazyva | mab | humanized | CD20 | Chronic lymphatic leukemia |
Ocaratuzumab[111] | mab | humanized | CD20 | cancer | |
Ocrelizumab[45] | mab | humanized | CD20 | rheumatoid arthritis, lupus erythematosus etc. | |
Odulimomab | mab | mouse | LFA-1 (CD11a) | prevention of organ transplant rejections, immunological diseases | |
Ofatumumab[22] | Arzerra | mab | human | CD20 | chronic lymphocytic leukemia etc. |
Olaratumab | mab | human | PDGF-R α | cancer | |
Olokizumab[79] | mab | humanized | IL6 | ? | |
Omalizumab[65] | Xolair | mab | humanized | IgE Fc region | allergic asthma |
Onartuzumab[112] | mab | humanized | human scatter factor receptor kinase | cancer | |
Ontuxizumab[113] | mab | chimeric/humanized | TEM1 | cancer | |
Opicinumab[114] | mab | human | LINGO-1 | multiple sclerosis | |
Oportuzumab monatox[106] | scFv | humanized | EpCAM | cancer | |
Oregovomab[69] | OvaRex | mab | mouse | CA-125 | ovarian cancer |
Orticumab[51] | mab | human | oxLDL | ? | |
Otelixizumab[10] | mab | chimeric/humanized | CD3 | diabetes mellitus type 1 | |
Otlertuzumab[115] | mab | humanized | CD37 | cancer | |
Oxelumab[116] | mab | human | OX-40 | asthma | |
Ozanezumab[117] | mab | humanized | NOGO-A | ALS and multiple sclerosis | |
Ozoralizumab[118] | mab | humanized | TNF-α | inflammation | |
Pagibaximab[22] | mab | chimeric | lipoteichoic acid | sepsis (Staphylococcus) | |
Palivizumab | Synagis, Abbosynagis | mab | humanized | F protein of respiratory syncytial virus | respiratory syncytial virus (prevention) |
Pamrevlumab[8] | mab | human | CTGF | ? | |
Panitumumab[68] | Vectibix | mab | human | EGFR | colorectal cancer |
Pankomab | mab | humanized | tumor specific glycosylation of MUC1 | ovarian cancer | |
Panobacumab[106] | mab | human | Pseudomonas aeruginosa | Pseudomonas aeruginosa infection | |
Parsatuzumab[51] | mab | human | EGFL7 | cancer | |
Pascolizumab[17] | mab | humanized | IL-4 | asthma | |
Pasotuxizumab[23] | mab | chimeric/humanized | folate hydrolase | cancer | |
Pateclizumab[30] | mab | humanized | LTA | TNF | |
Patritumab[37] | mab | human | ERBB3 (HER3) | cancer | |
Pembrolizumab[119] | mab | humanized | PDCD1 | cancer etc. | |
Pemtumomab | Theragyn | ? | mouse | MUC1 | cancer |
Perakizumab[51] | mab | humanized | IL 17A | arthritis | |
Pertuzumab | Omnitarg | mab | humanized | HER2/neu | cancer |
Pexelizumab[55] | scFv | humanized | C5 | reduction of side effects of cardiac surgery | |
Pidilizumab[120] | mab | humanized | PD-1 | cancer and infectious diseases | |
Pinatuzumab vedotin[26] | mab | humanized | CD22 | cancer | |
Pintumomab | mab | mouse | adenocarcinoma antigen | adenocarcinoma (imaging) | |
Placulumab[121] | mab | human | human TNF | pain and inflammatory diseases | |
Plozalizumab[8] | mab | humanized | CCR2 | diabetic nephropathy and arteriovenous graft patency | |
Pogalizumab[29] | mab | humanized | TNFR superfamily member 4 | ? | |
Polatuzumab vedotin[26][122] | mab | humanized | CD79B | cancer | |
Ponezumab[123] | mab | humanized | human beta-amyloid | Alzheimer's disease | |
Prezalizumab[29] | mab | humanized | ICOSL | ? | |
Priliximab | mab | chimeric | CD4 | Crohn's disease, multiple sclerosis | |
Pritoxaximab[26] | mab | chimeric | E. coli shiga toxin type-1 | ? | |
Pritumumab | mab | human | vimentin | brain cancer | |
PRO 140 | ? | humanized | CCR5 | HIV infection | |
Quilizumab[37] | mab | humanized | IGHE | asthma | |
Racotumomab[106] | mab | mouse | N-glycolylneuraminic acid | cancer | |
Radretumab[21] | mab | human | fibronectin extra domain-B | cancer | |
Rafivirumab[9] | mab | human | rabies virus glycoprotein | rabies (prophylaxis) | |
Ralpancizumab[124] | mab | humanized | neural apoptosis-regulated proteinase 1 | dyslipidemia | |
Ramucirumab | Cyramza | mab | human | VEGFR2 | solid tumors |
Ranibizumab[6] | Lucentis | Fab | humanized | VEGF-A | macular degeneration (wet form) |
Raxibacumab[24] | mab | human | anthrax toxin, protective antigen | anthrax (prophylaxis and treatment) | |
Refanezumab[125] | mab | humanized | myelin-associated glycoprotein | recovery of motor function after stroke | |
Regavirumab | mab | human | cytomegalovirus glycoprotein B | cytomegalovirus infection | |
Reslizumab[55] | mab | humanized | IL-5 | inflammations of the airways, skin and gastrointestinal tract | |
Rilotumumab[126] | mab | human | HGF | solid tumors | |
Rinucumab[127] | mab | human | platelet-derived growth factor receptor beta | neovascular age-related macular degeneration | |
Risankizumab[8] | mab | humanized | IL23A | ? | |
Rituximab | MabThera, Rituxan | mab | chimeric | CD20 | lymphomas, leukemias, some autoimmune disorders |
Rivabazumab pegol[8] | mab | humanized | Pseudomonas aeruginosa type III secretion system | ? | |
Robatumumab | mab | human | IGF-1 receptor (CD221) | cancer | |
Roledumab[79] | mab | human | RHD | ? | |
Romosozumab[128] | mab | humanized | sclerostin | osteoporosis | |
Rontalizumab[129] | mab | humanized | IFN-α | systemic lupus erythematosus | |
Rovalpituzumab tesirine[8] | mab | humanized | DLL3 | ? | |
Rovelizumab | LeukArrest | mab | humanized | CD11, CD18 | haemorrhagic shock etc. |
Ruplizumab[12] | Antova | mab | humanized | CD154 (CD40L) | rheumatic diseases |
Sacituzumab govitecan[130] | mab | humanized | tumor-associated calcium signal transducer 2 | cancer | |
Samalizumab[131] | mab | humanized | CD200 | cancer | |
Sapelizumab[29] | mab | humanized | IL6R | ? | |
Sarilumab[132] | mab | human | IL6 | rheumatoid arthritis, ankylosing spondylitis | |
Satumomab pendetide | mab | mouse | TAG-72 | cancer (diagnosis) | |
Secukinumab[133] | mab | human | IL 17A | uveitis, rheumatoid arthritis psoriasis | |
Seribantumab[26] | mab | human | ERBB3 (HER3) | cancer | |
Setoxaximab[26] | mab | chimeric | E. coli shiga toxin type-2 | ? | |
Sevirumab | ? | human | cytomegalovirus | cytomegalovirus infection | |
Sibrotuzumab | mab | humanized | FAP | cancer | |
SGN-CD19A | mab | humanized | CD19 | acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma | |
SGN-CD33A | mab | humanized | CD33 | Acute myeloid leukemia | |
Sifalimumab[134] | mab | humanized | IFN-α | SLE, dermatomyositis, polymyositis | |
Siltuximab | mab | chimeric | IL-6 | cancer | |
Simtuzumab[51] | mab | humanized | LOXL2 | fibrosis | |
Siplizumab[17] | mab | humanized | CD2 | psoriasis, graft-versus-host disease (prevention) | |
Sirukumab[135] | mab | human | IL-6 | rheumatoid arthritis | |
Sofituzumab vedotin[136] | mab | humanized | CA-125 | ovarian cancer | |
Solanezumab[106] | mab | humanized | beta amyloid | Alzheimer's disease | |
Solitomab[37] | BiTE | mouse | EpCAM | ? | |
Sonepcizumab[137] | ? | humanized | sphingosine-1-phosphate | choroidal and retinal neovascularization | |
Sontuzumab[108] | mab | humanized | episialin | ? | |
Stamulumab[45][108] | mab | human | myostatin | muscular dystrophy | |
Sulesomab | LeukoScan | Fab' | mouse | NCA-90 (granulocyte antigen) | osteomyelitis (imaging) |
Suvizumab[85] | mab | humanized | HIV-1 | viral infections | |
Tabalumab[138] | mab | human | BAFF | B-cell cancers | |
Tacatuzumab tetraxetan | AFP-Cide | mab | humanized | alpha-fetoprotein | cancer |
Tadocizumab[108] | Fab | humanized | integrin αIIbβ3 | percutaneous coronary intervention | |
Talizumab | mab | humanized | IgE | allergic reaction | |
Tamtuvetmab[29] | Tactress | mab | veterinary | CD52 | ? |
Tanezumab[9] | mab | humanized | NGF | pain | |
Taplitumomab paptox[65] | mab | mouse | CD19 | cancer | |
Tarextumab[139] | mab | human | Notch receptor | cancer | |
Tefibazumab[24] | Aurexis | mab | humanized | clumping factor A | Staphylococcus aureus infection |
Telimomab aritox | Fab | mouse | ? | ? | |
Tenatumomab[10] | mab | mouse | tenascin C | cancer | |
Teneliximab[17] | mab | chimeric | CD40 | autoimmune diseases and prevention of organ transplant rejection | |
Teplizumab[36] | mab | humanized | CD3 | diabetes mellitus type 1 | |
Teprotumumab[140] | mab | human | IGF-1 receptor (CD221) | hematologic tumors | |
Tesidolumab[20] | mab | human | C5 | ? | |
Tetulomab | mab | humanized | CD37 | cancer[141] | |
Tezepelumab[8] | mab | human | TSLP | asthma, atopic dermatitis | |
TGN1412 | ? | humanized | CD28 | chronic lymphocytic leukemia, rheumatoid arthritis | |
Ticilimumab (= tremelimumab) | mab | human | CTLA-4 | cancer | |
Tildrakizumab[142] | mab | humanized | IL23 | immunologically mediated inflammatory disorders | |
Tigatuzumab[10] | mab | humanized | TRAIL-R2 | cancer | |
Timolumab[29] | mab | human | AOC3 | ? | |
Tisotumab vedotin[8] | mab | human | coagulation factor III | ? | |
TNX-650 | ? | humanized | IL-13 | Hodgkin's lymphoma | |
Tocilizumab[6] (= atlizumab) | Actemra, RoActemra | mab | humanized | IL-6 receptor | rheumatoid arthritis |
Toralizumab[17] | mab | humanized | CD154 (CD40L) | rheumatoid arthritis, lupus nephritis etc. | |
Tosatoxumab[3] | mab | human | Staphylococcus aureus | ? | |
Tositumomab | Bexxar | ? | mouse | CD20 | follicular lymphoma |
Tovetumab[143] | mab | human | CD140a | cancer | |
Tralokinumab[144] | mab | human | IL-13 | asthma etc. | |
Trastuzumab | Herceptin | mab | humanized | HER2/neu | breast cancer |
Trastuzumab emtansine | Kadcyla | mab | humanized | HER2/neu | breast cancer |
TRBS07[145] | Ektomab | 3funct | ? | GD2 ganglioside | melanoma |
Tregalizumab[21] | mab | humanized | CD4 | ? | |
Tremelimumab | mab | human | CTLA-4 | cancer | |
Trevogrumab[146] | mab | human | growth differentiation factor 8 | muscle atrophy due to orthopedic disuse and sarcopenia | |
Tucotuzumab celmoleukin[45][108] | mab | humanized | EpCAM | cancer | |
Tuvirumab | ? | human | hepatitis B virus | chronic hepatitis B | |
Ublituximab[21] | mab | chimeric | MS4A1 | cancer | |
Ulocuplumab[147] | mab | human | CXCR4 (CD184) | hematologic malignancies | |
Urelumab[148] | mab | human | 4-1BB (CD137) | cancer etc. | |
Urtoxazumab[6] | mab | humanized | Escherichia coli | diarrhoea caused by E. coli | |
Ustekinumab[9] | Stelara | mab | human | IL-12, IL-23 | multiple sclerosis, psoriasis, psoriatic arthritis |
Utomilumab[32] | mab | human | 4-1BB (CD137) | cancer | |
Vadastuximab talirine[8] | mab | chimeric | CD33 | ? | |
Vandortuzumab vedotin[20] | mab | humanized | STEAP1 | cancer | |
Vantictumab[149] | mab | human | Frizzled receptor | cancer | |
Vanucizumab[23] | mab | humanized | angiopoietin 2 | cancer | |
Vapaliximab[17] | mab | chimeric | AOC3 (VAP-1) | ? | |
Varlilumab[150] | mab | human | CD27 | solid tumors and hematologic malignancies | |
Vatelizumab[30] | mab | humanized | ITGA2 (CD49b) | ? | |
Vedolizumab | mab | humanized | integrin α4β7 | Crohn's disease, ulcerative colitis | |
Veltuzumab[10] | mab | humanized | CD20 | non-Hodgkin's lymphoma | |
Vepalimomab | mab | mouse | AOC3 (VAP-1) | inflammation | |
Vesencumab[21] | mab | human | NRP1 | solid malignancies | |
Visilizumab[65] | Nuvion | mab | humanized | CD3 | Crohn's disease, ulcerative colitis |
Vobarilizumab[29] | mab | humanized | IL6R | inflammatory autoimmune diseases | |
Volociximab[22] | mab | chimeric | integrin α5β1 | solid tumors | |
Vorsetuzumab mafodotin[151] | mab | humanized | CD70 | cancer | |
Votumumab | HumaSPECT | mab | human | tumor antigen CTAA16.88 | colorectal tumors |
Xentuzumab[29] | mab | IGF1, IGF2 | ? | ||
Zalutumumab[22] | HuMax-EGFr | mab | human | EGFR | squamous cell carcinoma of the head and neck |
Zanolimumab[6] | HuMax-CD4 | mab | human | CD4 | rheumatoid arthritis, psoriasis, T-cell lymphoma |
Zatuximab[51] | mab | chimeric | HER1 | cancer | |
Ziralimumab[65] | mab | human | CD147 (basigin) | ? | |
Zolimomab aritox | mab | mouse | CD5 | systemic lupus erythematosus, graft-versus-host disease |
References
- 1 2 "United Therapeutics 10-K report". Retrieved 5 November 2011.
- 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 95" (PDF). WHO Drug Information. 20 (2).
- 1 2 3 4 5 6 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Abrilumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Actoxumab" (PDF). American Medical Association.
- 1 2 3 4 5 6 7 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 90" (PDF). WHO Drug Information. 18 (1).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Aducanumab" (PDF). American Medical Association.
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- 1 2 3 4 5 6 7 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 99" (PDF). WHO Drug Information. 22 (2).
- 1 2 3 4 5 6 7 8 9 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98" (PDF). WHO Drug Information. 21 (4).
- ↑ "BMS Shells Out $85M Up Front for Alder's Mid-Stage Rheumatoid Arthritis Antibody". Genetic Engineering & Biotechnology News. 10 November 2009.
- 1 2 3 4 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 83" (PDF). WHO Drug Information. 14 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Alirocumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Amatuximab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Anifrolumab" (PDF). American Medical Association.
- ↑ "Wyeth.com | Complete Project Listing". Wyeth. 2008. Archived from the original on June 12, 2008. Retrieved November 19, 2008.
- 1 2 3 4 5 6 7 8 9 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 87" (PDF). WHO Drug Information. 16 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ascrinvacumab" (PDF). American Medical Association.
- 1 2 3 World Health Organization (2003). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 88" (PDF). WHO Drug Information. 17 (1).
- 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
- 1 2 3 4 5 6 World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- 1 2 3 4 5 6 7 8 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 93" (PDF). WHO Drug Information. 19 (2).
- 1 2 3 4 5 6 7 8 9 10 World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
- 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 92" (PDF). WHO Drug Information. 18 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bezlotoxumab" (PDF). American Medical Association.
- 1 2 3 4 5 6 7 8 9 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bimagrumab" (PDF). American Medical Association.
- 1 2 World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Bococizumab" (PDF). American Medical Association.
- 1 2 3 4 5 World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brentuximab vedotin" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Briakinumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Brodalumab" (PDF). American Medical Association.
- 1 2 3 4 World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 97" (PDF). WHO Drug Information. 21 (2).
- 1 2 3 4 5 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Clazakizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Crenezumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dalotuzumab" (PDF). American Medical Association.
- 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101" (PDF). WHO Drug Information. 23 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Demcizumab" (PDF). American Medical Association.
- 1 2 3 4 5 6 7 World Health Organization (2005). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 94" (PDF). WHO Drug Information. 19 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Iodine I 131 Derlotuximab biotin" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dinutuximab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Diridavumab" (PDF). American Medical Association.
- ↑ World Health Organization (1991). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 66" (PDF). WHO Drug Information. 5 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.
- 1 2 3 4 5 6 7 8 9 10 11 12 World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dupilumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Durvalumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Dusigitumab" (PDF). American Medical Association.
- 1 2 3 4 World Health Organization (2001). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 85" (PDF). WHO Drug Information. 15 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Eldelumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Emibetuzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enfortumab Vedotin" (PDF). American Medical Association.
- ↑ World Health Organization (1997). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 77" (PDF). WHO Drug Information. 11 (2).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enoblituzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enokizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
- ↑ World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 51" (PDF). WHO Drug Information. 18 (1).
- 1 2 3 4 5 6 7 World Health Organization (2000). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 84" (PDF). WHO Drug Information. 14 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Evinacumab" (PDF). American Medical Association.
- 1 2 3 4 World Health Organization (2004). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 91" (PDF). WHO Drug Information. 18 (2).
- 1 2 3 World Health Organization (2002). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 86" (PDF). WHO Drug Information. 16 (12).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fasinumab" (PDF). American Medical Association.
- ↑ Buhmann, R; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H; Kolb, HJ; et al. (2008). "Immunotherapy of recurrent B–cell malignancies after allo SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion". Bone Marrow Transplantation. 43 (5): 383–397. doi:10.1038/bmt.2008.323. PMID 18850012.
|first2=
missing|last2=
in Authors list (help) - ↑ Boehrer, S; Mueller, Tina; Atz, Judith; Chow, Kai Uwe; et al. (2011). "Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanisms". Anti-Cancer Drugs. 12 (10): 3085–3091. doi:10.1097/CAD.0b013e328344887f.
|first2=
missing|last2=
in Authors list (help) - ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association.
- ↑ Clinical trial number NCT00883896 for "Study to Evaluate the Safety and Efficacy of ILV-094 in Subjects With Rheumatoid Arthritis" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00563524 for "Study Evaluating the Safety and Tolerability of ILV-094 in Subjects With Psoriasis" at ClinicalTrials.gov
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ficlatuzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fletikumab" (PDF). American Medical Association.
- 1 2 3 4 World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fresolimumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fulranumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Gevokizumab" (PDF). American Medical Association.
- ↑ http://www.prnewswire.com/news-releases/prometheus-obtains-exclusive-us-commercialization-rights-for-rencarex-121075044.html
- 1 2 World Health Organization (2009). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 102" (PDF). WHO Drug Information. 23 (4).
- ↑ NCI Drug Dictionary: Glemtumumab vedotin
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Guselkumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
- ↑ Clinical trial number NCT00537381 for "A Study of the Safety and Effectiveness of CNTO 95 in Patients With Metastatic Hormone Refractory Prostate Cancer" at ClinicalTrials.gov
- ↑ Clinical trial number NCT00246012 for "A Study of the Safety and Efficacy CNTO 95 in Subjects With Advanced Melanoma" at ClinicalTrials.gov
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Isatuximab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ixekizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lambrolizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lebrikizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lifastuzumab Vedotin" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ligelizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Lulizumab Pegol" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Margetuximab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mavrilimumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mirvetuximab Sorevtansine" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Moxetumomab Pasudotox" (PDF). American Medical Association.
- ↑ World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 96" (PDF). WHO Drug Information. 20 (4).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Narnatumab" (PDF). American Medical Association.
- 1 2 3 4 5 World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 100 (prepublication copy)" (PDF). WHO Drug Information.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Nesvacumab" (PDF). American Medical Association.
- 1 2 3 4 5 World Health Organization (2006). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 56" (PDF). WHO Drug Information. 20 (3).
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Nivolumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Obiltoxaximab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ocaratuzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ontuxizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Opicinumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Otlertuzumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ozanezumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ozoralizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Pembrolizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Pidilizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Placulumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Polatuzumab Vedotin" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ralpancizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Refanezumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rilotumumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rinucumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Romosozumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Rontalizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sacituzumab Govitecan" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Samalizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Secukinumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sifalimumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sofituzumab Vedotin" (PDF). American Medical Association.
- ↑ Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G.; Campochiaro, P. A. (2009). "Blockade of Sphingosine-1-phosphate Reduces Macrophage Influx and Retinal and Choroidal Neovascularization". Journal of Cellular Physiology. 218 (1): 192–198. doi:10.1002/jcp.21588. PMC 2905312
. PMID 18781584.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tarextumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Teprotumumab" (PDF). American Medical Association.
- ↑ Jostein Dahle, Ada H. V. Repetto-Llamazares, Camilla S. Mollatt, Katrine B. Melhus, Oyvind S. Bruland, Arne Kolstad & Roy H. Larsen (January 2013). "Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma". Anticancer research. 33 (1): 85–95. PMID 23267131.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tildrakizumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tovetumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tralokinumab" (PDF). American Medical Association.
- ↑ Ruf, P; Ellwart, J; Wosch, S; Kusterer, E; Lindhofer, H; et al. (2004). "Two new trifunctional antibodies for the therapy of human malignant melanoma". International Journal of Cancer. 108 (5): 725–732. doi:10.1002/ijc.11630. PMID 14696099.
|first2=
missing|last2=
in Authors list (help) - ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Trevogrumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ulocuplumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Vantictumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Varlilumab" (PDF). American Medical Association.
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Vorsetuzumab Mafodotin" (PDF). American Medical Association.
This article is issued from Wikipedia - version of the 9/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.